Were you told you can't take hormones because of cancer?
Maybe you're afraid hormones will give you cancer. Maybe you're a survivor and every door has closed on one word: never. Maybe your mother had breast cancer, or you carry a BRCA gene. This is for all of you, and the second half is built to print and bring to your appointment.
The trial behind the fear never tested your hormones
Most of the fear goes back to July 2002, when the Women's Health Initiative stopped a trial early and the headlines said hormones cause breast cancer. The pill in that trial was Premarin, a horse estrogen, plus MPA, a synthetic progestin. The trial never tested estradiol or progesterone; its women averaged 63, about 12 years past menopause. Here's what that study actually found.
The headline said 26% higher. In real women, that was 0.38% a year against 0.30% on placebo: about 8 extra breast cancers per 10,000 women a year. After twenty years of follow up, breast cancer deaths showed no significant difference.
The same program ran a second trial, Premarin alone with no progestin. It had fewer breast cancers, 238 against 296 on placebo, and about 40% fewer breast cancer deaths, 30 against 46. In 2013, the trial's own investigators pointed at the progestin. On November 10, 2025, the FDA asked for the breast cancer language to come out of the boxed warning on menopausal hormone therapy.
Your hormones are not the copycats
Estradiol is the hormone your ovaries made for decades. In randomized trials that gave it, breast cancer showed no increase: 5 cases against 5 on placebo (2001), and 10 against 17 over ten years in a Danish trial (2012), where women with a uterus also took a synthetic progestin. Estradiol has even been used to treat advanced breast cancer (2009).
Where a breast signal shows up, it follows the synthetic progestin, the same pattern as blood clots. In a large French cohort (2008), estradiol with micronized progesterone came out at 1.00, no increase, and estradiol with most synthetic progestins at 1.69. A British study (2020) found three different synthetic progestins landing in nearly the same spot, about 79% to 88% higher. Progesterone is not a progestin. They do opposite things.
The calendar matters too. Those French women took progesterone a mean of 22.5 days a month, leaving days with none. I do not cycle it. Every night.
Testosterone is the breast's brake
In a 2007 randomized trial, women on estradiol plus a synthetic progestin got a testosterone or placebo patch for six months. On placebo, dividing breast cells climbed more than fivefold. On testosterone, they barely moved. Women on testosterone pellets (2013) had 142 invasive breast cancers per 100,000 a year, against 276 expected. More on testosterone in women.
The bigger drivers carry no black box: excess body fat, tied to 13 cancers (2016), and alcohol, about 9% more breast cancer for every 10 grams a day (1998).
Your reference sheet: take this to your appointment
Each line names a year, so your provider can find it in the Sources below.
If you're afraid hormones will cause cancer
The 2002 trial tested Premarin plus MPA, not estradiol or progesterone.
Premarin alone lowered breast cancer deaths, 30 against 46 (2020).
Randomized trials of estradiol show no increase in breast cancer (2001, 2012, 2024).
Estradiol with micronized progesterone: no increase, 1.00 (2008).
Over 18 years, total cancer deaths did not differ on either Women's Health Initiative regimen (2017).
If you have a family history or a BRCA gene
A family history is a reason for genetic testing and closer screening, not a reason to refuse hormones. Women with and without one picked up about 7 and 5 extra cases per 1,000 on the 2002 pill, and the authors couldn't tell those increases apart (2009).
For BRCA carriers, removing the ovaries and tubes is recommended: about 80% fewer ovarian and tubal cancers and about half the breast cancer (2009). Then the hormones go back in without delay.
Carriers on hormone therapy had about half the breast cancer of 676 matched carriers who weren't started on it, and on estrogen alone, mostly estradiol, about 63% less (2026).
If you're a breast cancer survivor
The three main survivor trials gave estradiol with a synthetic progestin, or tibolone, a synthetic steroid (2005, 2008, 2009). Breast cancer deaths, or all deaths for tibolone, never differed.
The 2022 pooled analysis people quote drew nearly four in five women from the tibolone trial. Without it, the result was no longer significant. None of its trials tested estradiol with progesterone.
After pausing treatment, women pregnant by 18 months (the biggest dose of their own hormones) did no worse than those who weren't: 6.7% against 7.6% (2026).
For dryness and painful sex: vaginal testosterone in 20 survivors on aromatase inhibitors cut symptom scores by about two thirds, with estradiol under 8 pg/mL (2011). You don't need vaginal estradiol too.
Ask for both columns on tamoxifen and aromatase inhibitors. Tamoxifen's benefit: about 9 fewer breast cancer deaths per 100 at 15 years (2011). Cost: endometrial cancer 3.1% against 1.6% on ten years of tamoxifen instead of five (2013), and new pain in 57% within a year on an aromatase inhibitor (2017).
If you're a man with prostate cancer, or worried about it
"Never" began in 1941 with two castrated men and a blood enzyme. No tumor was measured.
Above a low level, the prostate stops responding: raising blood testosterone from about 280 to 640 didn't change testosterone inside the prostate (2006).
TRAVERSE: prostate cancer in 12 men on testosterone, 11 on placebo (2023).
Over 18 years, men who used testosterone had about half the risk of dying of prostate cancer (2023).
First placebo controlled testosterone trial in survivors, 136 men: no recurrence in either group over six months (2026).
If you survived ovarian, uterine or colorectal cancer
Ovarian cancer survivors, randomized: 53 of 75 on treatment, mostly Premarin, had died over a median of 19 years, against 68 of 75 without, about 37% lower risk of death (2015).
Endometrial cancer survivors, randomized, 1,236 women: recurrence 2.3% on estrogen against 1.9% on placebo (2006), and a 2018 review found no difference.
Colorectal cancer survivors: current hormone users had about 29% lower colorectal cancer death across five cohorts (2019).
Questions to ask, word for word
Which hormone: estradiol and progesterone, or Premarin and a synthetic progestin?
Did that study give the drug, or look at a database?
Out of how many people, over how many years?
Is that the chance of getting the cancer, or of dying of it?
Every day, or only part of the month?
Were the people in that study like me?
What does the treatment you're offering me cost, in absolute numbers?
Bring it in writing: your symptoms in your own words, what you take, and these questions. Ask for what informed consent already includes: the risks and benefits of each option, the alternatives, what happens if you do nothing, and your decision in the chart. That conversation includes your oncologist, always. Bring someone who isn't scared and isn't sick to hold the list.
If your provider won't look, you're allowed a second opinion. You can work with me, or find a clinician certified through WorldLink Medical in their provider directory. Nobody should stop a prescribed medication on their own because of an article.
The whole argument:
Listen to podcast Part One on Spotify
Listen to podcast Part Two on Spotify
⚠️ Educational content, not individual medical advice or a treatment recommendation. Nobody should start, stop or change a prescription because of an article. Your labs and history belong in a one on one.
🩺 DNP led telehealth hormone optimization. Book a consultation and find everything: withinyou.health/links
Sources
Adair, F. E., & Herrmann, J. B. (1946). The Use of Testosterone Propionate in the Treatment of Advanced Carcinoma of the Breast. Ann Surg, 123(6), 1023-35.
Ades, P. A. (2014). A controversial step forward: A commentary on the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Coron Artery Dis, 25(4), 360-3. https://doi.org/10.1097/MCA.0000000000000086
Agrawal, P., et al. (2024). Testosterone therapy in females is not associated with increased cardiovascular or breast cancer risk: a claims database analysis. J Sex Med, 21(5), 414-419. https://doi.org/10.1093/jsxmed/qdae032
Ahlering, T. E., et al. (2020). Testosterone replacement therapy reduces biochemical recurrence after radical prostatectomy. BJU Int, 126(1), 91-96. https://doi.org/10.1111/bju.15042
Amir, E., et al. (2011). Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst, 103(17), 1299-309. https://doi.org/10.1093/jnci/djr242
Anderson, G. L., et al. (2003). Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA, 290(13), 1739-48. https://doi.org/10.1001/jama.290.13.1739
Anderson, G. L., et al. (2012). Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol, 13(5), 476-86. https://doi.org/10.1016/S1470-2045(12)70075-X
AstraZeneca Pharmaceuticals LP. (2002). NOLVADEX (tamoxifen citrate) tablets: Prescribing information (NDA 17-970/S-049, Rev 05-02). U.S. Food and Drug Administration, Drugs@FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/17970s37s44s49lbl.pdf
Baik, S. H., et al. (2026). Association Between Testosterone Replacement Therapy and Prostatic Disorders in Elderly Hypogonadal Men. J Clin Endocrinol Metab, 111(3), e794-e810. https://doi.org/10.1210/clinem/dgaf504
Barakat, R. R., et al. (2006). Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol, 24(4), 587-92. https://doi.org/10.1200/JCO.2005.02.8464
Becker, T., et al. (2012). Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. J Am Geriatr Soc, 60(9), 1761-7. https://doi.org/10.1111/j.1532-5415.2012.04107.x
Berrino, F., et al. (2005). Serum testosterone levels and breast cancer recurrence. Int J Cancer, 113(3), 499-502. https://doi.org/10.1002/ijc.20582
Bhasin, S., et al. (2023). Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open, 6(12), e2348692. https://doi.org/10.1001/jamanetworkopen.2023.48692
Bhasin, S., et al. (2026). Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial. JAMA Intern Med, 186(7), 805-814. https://doi.org/10.1001/jamainternmed.2026.1343
Bolla, M., et al. (1997). Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med, 337(5), 295-300. https://doi.org/10.1056/NEJM199707313370502
Boyle, P., et al. (2016). Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int, 118(5), 731-741. https://doi.org/10.1111/bju.13417
Brinton, L. A., & Felix, A. S. (2014). Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol, 142, 83-9. https://doi.org/10.1016/j.jsbmb.2013.05.001
Brinton, L. A., et al. (2014). Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst, 106(3), djt465. https://doi.org/10.1093/jnci/djt465
Buttros, D. A. B., et al. (2019). High risk for cardiovascular disease in postmenopausal breast cancer survivors. Menopause, 26(9), 1024-1030. https://doi.org/10.1097/GME.0000000000001348
Carling, C. L., et al. (2009). The effect of alternative summary statistics for communicating risk reduction on decisions about taking statins: a randomized trial. PLoS Med, 6(8), e1000134. https://doi.org/10.1371/journal.pmed.1000134
Chan, J. A., et al. (2006). Hormone replacement therapy and survival after colorectal cancer diagnosis. J Clin Oncol, 24(36), 5680-6. https://doi.org/10.1200/JCO.2006.08.0580
Chlebowski, R. T., et al. (2004). Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med, 350(10), 991-1004. https://doi.org/10.1056/NEJMoa032071
Chlebowski, R. T., et al. (2009). Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet, 374(9697), 1243-51. https://doi.org/10.1016/S0140-6736(09)61526-9
Chlebowski, R. T., et al. (2010a). Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA, 304(15), 1684-92. https://doi.org/10.1001/jama.2010.1500
Chlebowski, R. T., et al. (2010b). Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst, 102(18), 1413-21. https://doi.org/10.1093/jnci/djq285
Chlebowski, R. T., et al. (2016). Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial. J Natl Cancer Inst, 108(3). https://doi.org/10.1093/jnci/djv350
Chlebowski, R. T., et al. (2020). Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. JAMA, 324(4), 369-380. https://doi.org/10.1001/jama.2020.9482
Chlebowski, R. T., et al. (2024a). Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials. J Clin Oncol, 42(30), 3537-3549. https://doi.org/10.1200/JCO.23.01918
Chlebowski, R. T., et al. (2024b). Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis. Breast Cancer Res Treat, 206(1), 177-184. https://doi.org/10.1007/s10549-024-07307-9
Cholesterol Treatment Trialists' (CTT) Collaboration. (2024). Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol, 12(5), 306-319. https://doi.org/10.1016/S2213-8587(24)00040-8
Clague, J., et al. (2011). Menopausal hormone therapy does not influence lung cancer risk: results from the California Teachers Study. Cancer Epidemiol Biomarkers Prev, 20(3), 560-4. https://doi.org/10.1158/1055-9965.EPI-10-1182
Coelingh Bennink, H. J., et al. (2017). The use of high-dose estrogens for the treatment of breast cancer. Maturitas, 95, 11-23. https://doi.org/10.1016/j.maturitas.2016.10.010
Cold, S., et al. (2022). Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study. J Natl Cancer Inst, 114(10), 1347-1354. https://doi.org/10.1093/jnci/djac112
Collaborative Group on Epidemiological Studies of Ovarian Cancer. (2015). Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet, 385(9980), 1835-42. https://doi.org/10.1016/S0140-6736(14)61687-1
Collaborative Group on Hormonal Factors in Breast Cancer. (2019). Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet, 394(10204), 1159-1168. https://doi.org/10.1016/S0140-6736(19)31709-X
Cordina-Duverger, E., et al. (2013). Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One, 8(11), e78016. https://doi.org/10.1371/journal.pone.0078016
Coronado, P. J., et al. (2024). Eligibility criteria for using menopausal hormone therapy in breast cancer survivors: a safety report based on a systematic review and meta-analysis. Menopause, 31(3), 234-242. https://doi.org/10.1097/GME.0000000000002317
Crandall, C. J., et al. (2018). Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause, 25(1), 11-20. https://doi.org/10.1097/GME.0000000000000956
Davies, C., et al. (2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet, 381(9869), 805-16. https://doi.org/10.1016/S0140-6736(12)61963-1
de Lignières, B., et al. (2002). Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric, 5(4), 332-40. https://doi.org/10.1080/713605312
Demasi, M. (2018). Statin wars: have we been misled about the evidence? A narrative review. Br J Sports Med, 52(14), 905-909. https://doi.org/10.1136/bjsports-2017-098497
Dimitrakakis, C., et al. (2004). Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause, 11(5), 531-5. https://doi.org/10.1097/01.gme.0000119983.48235.d3
Donovitz, G., & Cotten, M. (2021). Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study. Eur J Breast Health, 17(2), 150-156. https://doi.org/10.4274/ejbh.galenos.2021.6213
Dowsett, M., et al. (2010). Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol, 28(3), 509-18. https://doi.org/10.1200/JCO.2009.23.1274
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378(9793), 771-84. https://doi.org/10.1016/S0140-6736(11)60993-8
Eastell, R., et al. (2008). Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol, 26(7), 1051-7. https://doi.org/10.1200/JCO.2007.11.0726
Edey, K. A., et al. (2018). Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev, 5(5), CD008830. https://doi.org/10.1002/14651858.CD008830.pub3
Eeles, R. A., et al. (2015). Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial. J Clin Oncol, 33(35), 4138-44. https://doi.org/10.1200/JCO.2015.60.9719
Ellis, M. J., et al. (2009). Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA, 302(7), 774-80. https://doi.org/10.1001/jama.2009.1204
Fahlén, M., et al. (2013). Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer, 49(1), 52-9. https://doi.org/10.1016/j.ejca.2012.07.003
Fels, E. (1944). Treatment of breast cancer with testosterone propionate: A preliminary report. J Clin Endocrinol, 4(3), 121-125. https://doi.org/10.1210/jcem-4-3-121
Fisher, B., et al. (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst, 90(18), 1371-88. https://doi.org/10.1093/jnci/90.18.1371
Fisher, B., et al. (2005). Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst, 97(22), 1652-62. https://doi.org/10.1093/jnci/dji372
Fournier, A., et al. (2008). Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat, 107(1), 103-11. https://doi.org/10.1007/s10549-007-9523-x
Fournier, A., et al. (2014a). Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res Treat, 145(2), 535-43. https://doi.org/10.1007/s10549-014-2934-6 (Read via Stute et al., 2018.)
Fournier, A., et al. (2014b). Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008. Am J Epidemiol, 180(5), 508-17. https://doi.org/10.1093/aje/kwu146
Frandsen, C. L. B., et al. (2024). Polycystic ovary syndrome and risk of breast cancer in premenopausal and postmenopausal women: a nationwide population-based cohort study. Breast Cancer Res Treat, 208(3), 535-542. https://doi.org/10.1007/s10549-024-07467-8
Gan, S., et al. (2022). Low serum total testosterone level as a predictor of upgrading in low-risk prostate cancer patients after radical prostatectomy: A systematic review and meta-analysis. Investig Clin Urol, 63(4), 407-414. https://doi.org/10.4111/icu.20210459
Ghanavati, M., et al. (2023). Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose-response meta-analysis. Cancer Rep (Hoboken), 6(4), e1806. https://doi.org/10.1002/cnr2.1806
Gilbert, D. C., et al. (2017). Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. BJU Int, 119(5), 667-675. https://doi.org/10.1111/bju.13687
Glaser, R. L., & Dimitrakakis, C. (2013). Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study. Maturitas, 76(4), 342-9. https://doi.org/10.1016/j.maturitas.2013.08.002
Glaser, R. L., et al. (2019). Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study. BMC Cancer, 19(1), 1271. https://doi.org/10.1186/s12885-019-6457-8
Glynne, S., et al. (2026). Menopausal hormone therapy for breast cancer patients: what is the current evidence?. Menopause, 33(1), 88-117. https://doi.org/10.1097/GME.0000000000002627
Grady, D., et al. (2007). Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women. Menopause, 14(3 Pt 1), 391-6. https://doi.org/10.1097/01.gme.0000236939.81819.6c
Gramling, R., et al. (2009). Hormone replacement therapy, family history, and breast cancer risk among postmenopausal women. Epidemiology, 20(5), 752-6. https://doi.org/10.1097/EDE.0b013e3181a71279
Guidozzi, F., & Daponte, A. (1999). Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer, 86(6), 1013-8. https://doi.org/10.1002/(sici)1097-0142(19990915)86:6<1013::aid-cncr17>3.0.co;2-1
Haddow, A., et al. (1944). Influence of Synthetic Oestrogens on Advanced Malignant Disease. Br Med J, 2(4368), 393-8. https://doi.org/10.1136/bmj.2.4368.393
Hamood, R., et al. (2018). Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study. J Clin Oncol, 36(20), 2061-2069. https://doi.org/10.1200/JCO.2017.76.3524
Harbs, J., et al. (2022). Circulating Sex Hormone Levels and Colon Cancer Risk in Men: A Nested Case-Control Study and Meta-Analysis. Cancer Epidemiol Biomarkers Prev, 31(4), 793-803. https://doi.org/10.1158/1055-9965.EPI-21-0996
Hickey, M., et al. (2024). What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO). Gynecol Oncol, 191, 201-211. https://doi.org/10.1016/j.ygyno.2024.10.007
Hipolito Rodrigues, M. A., & Gompel, A. (2021). Micronized progesterone, progestins, and menopause hormone therapy. Women Health, 61(1), 3-14. https://doi.org/10.1080/03630242.2020.1824956
Hodis, H. N., & Mack, W. J. (2008). In Perspective: Estrogen Therapy Proves to Safely and Effectively Reduce Total Mortality and Coronary Heart Disease in Recently Postmenopausal Women. Menopause Manag, 17(2), 27-32.
Hodis, H. N., & Sarrel, P. M. (2018). Menopausal hormone therapy and breast cancer: what is the evidence from randomized trials?. Climacteric, 21(6), 521-528. https://doi.org/10.1080/13697137.2018.1514008
Hofling, M., et al. (2007). Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause, 14(2), 183-90. https://doi.org/10.1097/01.gme.0000232033.92411.51
Holmberg, L., & Anderson, H. (2004). HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. Lancet, 363(9407), 453-5. https://doi.org/10.1016/S0140-6736(04)15493-7
Holmberg, L., et al. (2008). Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst, 100(7), 475-82. https://doi.org/10.1093/jnci/djn058
Huggins, C., & Hodges, C. V. (2002). Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol, 168(1), 9-12. https://doi.org/10.1016/s0022-5347(05)64820-3 (Original work published 1941)
Ingle, J. N., et al. (1981). Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med, 304(1), 16-21. https://doi.org/10.1056/NEJM198101013040104
Islam, R. M., et al. (2019). Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol, 7(10), 754-766. https://doi.org/10.1016/S2213-8587(19)30189-5
Jaakkola, S., et al. (2009). Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol, 114(6), 1197-1204. https://doi.org/10.1097/AOG.0b013e3181bea950
Jang, Y. C., et al. (2019). Association of hormone replacement therapy with mortality in colorectal cancer survivor: a systematic review and meta-analysis. BMC Cancer, 19(1), 1199. https://doi.org/10.1186/s12885-019-6428-0
Janssen, J. A. M. J. L. (2021). Hyperinsulinemia and Its Pivotal Role in Aging, Obesity, Type 2 Diabetes, Cardiovascular Disease and Cancer. Int J Mol Sci, 22(15). https://doi.org/10.3390/ijms22157797
Kacker, R., et al. (2016). Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl, 18(1), 16-20. https://doi.org/10.4103/1008-682X.160270
Keating, N. L., et al. (2006). Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol, 24(27), 4448-56. https://doi.org/10.1200/JCO.2006.06.2497
Kenemans, P., et al. (2009). Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol, 10(2), 135-46. https://doi.org/10.1016/S1470-2045(08)70341-3
Koch, T., et al. (2022). Bilateral oophorectomy and rate of colorectal cancer: A prospective cohort study. Int J Cancer, 150(1), 38-46. https://doi.org/10.1002/ijc.33776
Kotsopoulos, J., et al. (2024). Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations. JAMA Oncol, 10(4), 484-492. https://doi.org/10.1001/jamaoncol.2023.6937
Kotsopoulos, J., et al. (2026). Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2. J Natl Cancer Inst, 118(5), 856-864. https://doi.org/10.1093/jnci/djaf363
Lalitkumar, P. G. L., et al. (2023). Effects of Estradiol/Micronized Progesterone vs. Conjugated Equine Estrogens/Medroxyprogesterone Acetate on Breast Cancer Gene Expression in Healthy Postmenopausal Women. Int J Mol Sci, 24(4). https://doi.org/10.3390/ijms24044123
Langley, R. E., et al. (2026). Transdermal Estradiol Patches in Locally Advanced Prostate Cancer. N Engl J Med, 394(16), 1595-1607. https://doi.org/10.1056/NEJMoa2511781
Laroche, F., et al. (2017). Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study. PLoS One, 12(11), e0187165. https://doi.org/10.1371/journal.pone.0187165
Lauby-Secretan, B., et al. (2016). Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med, 375(8), 794-8. https://doi.org/10.1056/NEJMsr1606602
Li, Y., et al. (2017). Melatonin for the prevention and treatment of cancer. Oncotarget, 8(24), 39896-39921. https://doi.org/10.18632/oncotarget.16379
Lincoff, A. M., et al. (2023). Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med, 389(2), 107-117. https://doi.org/10.1056/NEJMoa2215025
Lipscombe, L. L., et al. (2012). Association between tamoxifen treatment and diabetes: a population-based study. Cancer, 118(10), 2615-22. https://doi.org/10.1002/cncr.26559
Lobo, R. A., et al. (2018). A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial. Obstet Gynecol, 132(1), 161-170. https://doi.org/10.1097/AOG.0000000000002645
Loeb, S., et al. (2017). Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer. J Clin Oncol, 35(13), 1430-1436. https://doi.org/10.1200/JCO.2016.69.5304
Luo, G., et al. (2016). Risk of colorectal cancer with hysterectomy and oophorectomy: A systematic review and meta-analysis. Int J Surg, 34, 88-95. https://doi.org/10.1016/j.ijsu.2016.08.518
Manson, J. E., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 310(13), 1353-68. https://doi.org/10.1001/jama.2013.278040
Manson, J. E., et al. (2017). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA, 318(10), 927-938. https://doi.org/10.1001/jama.2017.11217
Marchetti, C., et al. (2018). Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis. Crit Rev Oncol Hematol, 132, 111-115. https://doi.org/10.1016/j.critrevonc.2018.09.018
Marks, L. S., et al. (2006). Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA, 296(19), 2351-61. https://doi.org/10.1001/jama.296.19.2351
Marriott, R. J., et al. (2026). Associations of testosterone, sex hormone-binding globulin, and related hormones with risks of cancer death, incident cancer, and incident prostate cancer in men: individual participant data meta-analyses. Lancet Healthy Longev, 7(6), 100857. https://doi.org/10.1016/j.lanhl.2026.100857
Meaidi, A., et al. (2024). Association of vaginal oestradiol and the rate of breast cancer in Denmark: registry based, case-control study, nested in a nationwide cohort. BMJ Med, 3(1), e000753. https://doi.org/10.1136/bmjmed-2023-000753
Melisko, M. E., et al. (2017). Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol, 3(3), 313-319. https://doi.org/10.1001/jamaoncol.2016.3904
Mikkola, T. S., et al. (2016). Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study. Menopause, 23(11), 1199-1203. https://doi.org/10.1097/GME.0000000000000698
Million Women Study Collaborators. (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 362(9382), 419-27. https://doi.org/10.1016/s0140-6736(03)14065-2
Mirkin, S. (2018). Evidence on the use of progesterone in menopausal hormone therapy. Climacteric, 21(4), 346-354. https://doi.org/10.1080/13697137.2018.1455657
Montz, F. J., et al. (2002). Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol, 186(4), 651-7. https://doi.org/10.1067/mob.2002.122130
Morales, A., & Siemens, D. R. (2022). Testosterone Therapy and Prostate Cancer: Incorporating Low-Level Evidence into Practical Recommendations. Urol Clin North Am, 49(4), 573-582. https://doi.org/10.1016/j.ucl.2022.07.002
Morgentaler, A., & Rhoden, E. L. (2006). Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology, 68(6), 1263-7. https://doi.org/10.1016/j.urology.2006.08.1058
Morgentaler, A., et al. (2014). Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months. J Sex Med, 11(11), 2818-25. https://doi.org/10.1111/jsm.12657
Murkes, D., et al. (2012). Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo. Gynecol Endocrinol, 28 Suppl 2, 12-5. https://doi.org/10.3109/09513590.2012.706670
Pagani, O., et al. (2026). Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial. Ann Oncol, 37(9), 1230-1241. https://doi.org/10.1016/j.annonc.2026.05.699
Park, J., et al. (2016). Low testosterone level is an independent risk factor for high-grade prostate cancer detection at biopsy. BJU Int, 118(2), 230-5. https://doi.org/10.1111/bju.13206
Parker, W. H., et al. (2013). Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstet Gynecol, 121(4), 709-716. https://doi.org/10.1097/AOG.0b013e3182864350
Partridge, A. H., et al. (2008). Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol, 26(4), 556-62. https://doi.org/10.1200/JCO.2007.11.5451
Partridge, A. H., et al. (2023). Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. N Engl J Med, 388(18), 1645-1656. https://doi.org/10.1056/NEJMoa2212856
Peethambaram, P. P., et al. (1999). Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat, 54(2), 117-22. https://doi.org/10.1023/a:1006185805079
Pencina, K. M., et al. (2021). A Selective Androgen Receptor Modulator (OPK-88004) in Prostate Cancer Survivors: A Randomized Trial. J Clin Endocrinol Metab, 106(8), 2171-2186. https://doi.org/10.1210/clinem/dgab361
Planck, T., et al. (2021). Liothyronine Use in Hypothyroidism and its Effects on Cancer and Mortality. Thyroid, 31(5), 732-739. https://doi.org/10.1089/thy.2020.0388
Poggio, F., et al. (2022). Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat, 191(2), 269-275. https://doi.org/10.1007/s10549-021-06436-9
Purvis, J. (2002, May 15). Dear Doctor letter: Changes to NOLVADEX (tamoxifen citrate) prescribing information, boxed warning for women with DCIS and women at high risk for breast cancer [Letter]. AstraZeneca Pharmaceuticals LP.
Rajpathak, S. N., et al. (2009). Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care, 32(10), 1924-9. https://doi.org/10.2337/dc09-0738
Ramos, E., et al. (2023). Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review. Pharmaceutics, 15(6). https://doi.org/10.3390/pharmaceutics15061616
Rebbeck, T. R., et al. (2005). Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol, 23(31), 7804-10. https://doi.org/10.1200/JCO.2004.00.8151
Rebbeck, T. R., et al. (2009). Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst, 101(2), 80-7. https://doi.org/10.1093/jnci/djn442
Ridker, P. M., et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 359(21), 2195-207. https://doi.org/10.1056/NEJMoa0807646
Ridker, P. M., et al. (2012). Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet, 380(9841), 565-71. https://doi.org/10.1016/S0140-6736(12)61190-8
Rock, C. L., et al. (2008). Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomarkers Prev, 17(3), 614-20. https://doi.org/10.1158/1055-9965.EPI-07-0761
Roddam, A. W., et al. (2008). Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst, 100(3), 170-83. https://doi.org/10.1093/jnci/djm323
Ryan, C. J., et al. (2013). Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol, 31(22), 2791-8. https://doi.org/10.1200/JCO.2012.45.4595
Saeaib, N., et al. (2020). Hormone replacement therapy after surgery for epithelial ovarian cancer. Cochrane Database Syst Rev, 1(1), CD012559. https://doi.org/10.1002/14651858.CD012559.pub2
Santen, R. J., et al. (2013). Occult breast tumor reservoir: biological properties and clinical significance. Horm Cancer, 4(4), 195-207. https://doi.org/10.1007/s12672-013-0145-y
Sarkar, F. H., & Li, Y. (2004). Indole-3-carbinol and prostate cancer. J Nutr, 134(12 Suppl), 3493S-3498S. https://doi.org/10.1093/jn/134.12.3493S
Sarkar, R. R., et al. (2020). Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease. Prostate Cancer Prostatic Dis, 23(4), 689-695. https://doi.org/10.1038/s41391-020-0241-3
Schernhammer, E. S., & Hankinson, S. E. (2005). Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst, 97(14), 1084-7. https://doi.org/10.1093/jnci/dji190
Schernhammer, E. S., et al. (2008). Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst, 100(12), 898-905. https://doi.org/10.1093/jnci/djn171
Schierbeck, L. L., et al. (2012). Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ, 345, e6409. https://doi.org/10.1136/bmj.e6409
Schwartz, A. G., et al. (2007). Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol, 25(36), 5785-92. https://doi.org/10.1200/JCO.2007.13.3975
Scott, O. W., et al. (2023). Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study. Breast Cancer Res Treat, 199(1), 195-206. https://doi.org/10.1007/s10549-022-06815-w
Seely, D., et al. (2012). Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther, 11(4), 293-303. https://doi.org/10.1177/1534735411425484
Severi, G., et al. (2006). Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 15(1), 86-91. https://doi.org/10.1158/1055-9965.EPI-05-0633
Shahinian, V. B., et al. (2005). Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med, 352(2), 154-64. https://doi.org/10.1056/NEJMoa041943
Siltari, A., et al. (2023). Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men. Acta Oncol, 62(12), 1898-1904. https://doi.org/10.1080/0284186X.2023.2278189
Slomski, A. (2020). Which Postmenopausal Women Should Use Testosterone for Low Sexual Desire?. JAMA, 323(6), 493-495. https://doi.org/10.1001/jama.2019.22070
Smith-Warner, S. A., et al. (1998). Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA, 279(7), 535-40. https://doi.org/10.1001/jama.279.7.535
Stute, P., et al. (2018). The impact of micronized progesterone on breast cancer risk: a systematic review. Climacteric, 21(2), 111-122. https://doi.org/10.1080/13697137.2017.1421925
Suriano, K. A., et al. (2001). Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol, 97(4), 555-60. https://doi.org/10.1016/s0029-7844(00)01221-7
Symer, M. M., et al. (2018). Hormone Replacement Therapy and Colorectal Cancer Incidence and Mortality in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Clin Colorectal Cancer, 17(2), e281-e288. https://doi.org/10.1016/j.clcc.2018.01.003
Tamimi, R. M., et al. (2006). Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med, 166(14), 1483-9. https://doi.org/10.1001/archinte.166.14.1483
Teply, B. A., et al. (2018). Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol, 19(1), 76-86. https://doi.org/10.1016/S1470-2045(17)30906-3
Thorneloe, R. J., et al. (2020). Knowledge of Potential Harms and Benefits of Tamoxifen among Women Considering Breast Cancer Preventive Therapy. Cancer Prev Res (Phila), 13(4), 411-422. https://doi.org/10.1158/1940-6207.CAPR-19-0424
Traish, A. M., & Morgentaler, A. (2022). Androgen Therapy in Women with Testosterone Insufficiency: Looking Back and Looking Ahead. Androgens: Clinical Research and Therapeutics, 3(1), 2-13. https://doi.org/10.1089/andro.2021.0030
Tseng, F. Y., et al. (2015). Subclinical hypothyroidism is associated with increased risk for cancer mortality in adult Taiwanese-a 10 years population-based cohort. PLoS One, 10(4), e0122955. https://doi.org/10.1371/journal.pone.0122955
Ursin, G., et al. (1999). Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst, 91(12), 1067-72. https://doi.org/10.1093/jnci/91.12.1067
U.S. Food and Drug Administration. (2004, October 28). Advisory Committee for Reproductive Health Drugs; notice of meeting [NDA 21-769, testosterone transdermal system]. Federal Register, 69(208), 62902. FR Doc. 04-24068.
U.S. Food and Drug Administration. (2025a). HRT bibliography [Literature list linked from the November 2025 menopausal hormone therapy labeling-change notice; FDA /media/189657].
U.S. Food and Drug Administration. (2025b, November 10). FDA requests labeling changes related to safety information to clarify the benefit/risk considerations for menopausal hormone therapies [Drug safety communication].
Vinogradova, Y., et al. (2020). Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ, 371, m3873. https://doi.org/10.1136/bmj.m3873
Viscoli, C. M., et al. (2001). A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med, 345(17), 1243-9. https://doi.org/10.1056/NEJMoa010534
von Schoultz, E., & Rutqvist, L. E. (2005). Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst, 97(7), 533-5. https://doi.org/10.1093/jnci/dji071
Walsh, J. M., & Pignone, M. (2004). Drug treatment of hyperlipidemia in women. JAMA, 291(18), 2243-52. https://doi.org/10.1001/jama.291.18.2243
Wang, Y. M., et al. (2012). The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol, 69(5), 1213-20. https://doi.org/10.1007/s00280-012-1828-8
Wickerham, D. L., et al. (2002). Association of tamoxifen and uterine sarcoma. J Clin Oncol, 20(11), 2758-60. https://doi.org/10.1200/JCO.2002.20.11.2758
Witherby, S., et al. (2011). Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist, 16(4), 424-31. https://doi.org/10.1634/theoncologist.2010-0435
Writing Group for the Women's Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321-33. https://doi.org/10.1001/jama.288.3.321
Wysowski, D. K., et al. (2002). Uterine sarcoma associated with tamoxifen use. N Engl J Med, 346(23), 1832-3. https://doi.org/10.1056/NEJM200206063462319
Zhang, Y., et al. (2026). Adverse events associated with statin co-use in breast cancer patients: a disproportionality analysis based on the FDA Adverse Event Reporting System. Ther Adv Drug Saf, 17, 20420986261450026. https://doi.org/10.1177/20420986261450026
